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Volumetric Modulated Arc Therapy for Advanced 
Pancreatic Cancer
Wietse Eppinga, Frank Lagerwaard, Wilko Verbakel, Ben Slotman, Suresh Senan1
Background: Intensity-modulated radiotherapy (IMRT) allows for improved sparing of organs at risk (OARs) in advanced pan-
creatic cancer. A planning study evaluated if volumetric modulated arc therapy (RapidArc™ [RA]) could be used as an alternative 
to IMRT in such cases.
Patients and Methods: In ten patients, five-field IMRT (5f-IMRT) plans with fixed gantry positions were compared to RA plans 
using similar constraints for planning target volume (PTV) and OARs. PTV coverage, conformity indices (CI), and OAR doses were 
compared. One patient was treated using RA and calculated dose distributions were measured in coronal planes in a solid-water 
phantom.
Results: RA plans showed superior mean CI of 1.09 ± 0.02 (± 1 SD [standard deviation]) versus 1.20 ± 0.10 in 5f-IMRT 
(p = 0.003). Both techniques achieved similar sparing of the right kidney, but RA significantly reduced left kidney doses with 
V15 of 7.2% ± 5.3% and 15.9% ± 11.1%, respectively; p = 0.02. RA modestly decreased mean doses to liver (13.8 vs. 15.1 Gy; 
p = 0.003), stomach (16.7 vs. 17.9 Gy; p = 0.017), small bowel (19.8 vs. 22.1 Gy; p < 0.001), and duodenum (38.8 vs. 41.9 Gy; 
p = 0.004). Film dosimetry revealed excellent agreement between calculated and measured dose distributions. The delivery time 
for RA was < 3 min.
Conclusion: RA planning achieved superior CI for pancreatic tumors compared to 5f-IMRT, and modestly reduced OAR doses. Fast 
treatment delivery using RA may decrease the risk of intrafractional organ motion.
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„Volumetric modulated arc therapy“ bei lokal fortgeschrittenem Pankreaskarzinom
Hintergrund: Durch intensitätsmodulierte Radiotherapie (IMRT) ergibt sich die Möglichkeit einer niedrigeren Dosisverteilung 
hinsichtlich der Risikoorgane (OAR) bei Patienten mit lokal fortgeschrittenem Pankreaskarzinom. Die vorliegende Planungsstudie 
soll die Frage beantworten, ob „volumetric modulated arc therapy“ (RapidArc™ [RA]) eine Alternative zur IMRT sein könnte.
Patienten und Methodik: Bei zehn Patienten wurden Fünf-Felder-IMRT-Pläne mit fester Gantryposition und RA-Plänen bei nahe-
zu identischen Beschränkungen bezüglich Planungszielvolumen (PTV) und OAR verglichen. Analysiert und verglichen wurden Ab-
deckung des PTV, Konformitätsindizes (CI) und OAR-Dosen. Ein Patient wurde mittels RA-Technik behandelt. Dosiskalkulationen 
erfolgten anhand im Wasserphantom gemessener koronaler Dosisverteilungen.
Ergebnisse: RA-Pläne zeigten einen günstigeren CI von 1,09 ± 0,02 (± 1 SD [Standardabweichung]) gegenüber 1,20 ± 0,10 bei 
5f-IMRT (p = 0,003). Mit beiden Techniken gelang eine zufriedenstellende Dosisreduktion der rechten Niere, mittels RA konnten 
jedoch die V15 der linken Niere signifikant reduziert werden (7,2% ± 5,3% vs. 15,9% ± 11,1% bei IMRT; p = 0,02). Geringer zeigte 
sich die Reduktion der mittleren Dosis der Leber (13,8 vs. 15,1 Gy; p = 0,003), des Magens (16,7 vs. 17,9 Gy; p = 0,017), des 
Dünndarms (19,8 vs. 22,1 Gy; p < 0,001) und des Duodenums (38,8 vs. 41,9 Gy; p = 0,004). Filmdosimetrische Überprüfungen 
zeigten hervorragende Übereinstimmungen bezüglich kalkulierter und tatsächlicher Dosisverteilung. Die Gesamtbestrahlungszeit 
betrug < 3 min.
Schlussfolgerung: Mittels RA-Planung lässt sich im Vergleich zur 5f-IMRT sowohl ein günstigerer CI als auch moderate Dosisreduk-
tion in den OAR erreichen. Durch die rasche Dosisapplikation vermindert sich das Risiko intrafraktionärer Bewegung der OAR.
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Planungsstudie · Risikoorgane
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Introduction
In locally advanced pancreatic cancer, primary chemoradio-
therapy appears to be superior to best supportive care and 
high-dose radiotherapy alone [14]. In selected patients, neo-
adjuvant treatment can result in downstaging of pancreatic 
tumors and nodal spread [32] and adjuvant chemoradiother-
apy should be considered after irradical resections [20]. How-
ever, previous randomized studies have reported significantly 
higher rates of hematologic and gastrointestinal toxicity with 
chemoradiotherapy [8, 10, 27]. Late toxicity after chemoradio-
therapy to the upper abdomen includes bowel strictures [16, 
27] and radiation-induced nephropathy, which may manifest 
months to years post-treatment [7, 15]. Measures to reduce 
toxicity include omitting prophylactic radiotherapy of region-
al lymph nodes [27], decreasing mobility margins by individu-
alized assessment and incorporation of target mobility [33], 
and the use of more conformal radiotherapy techniques. In 
particular, use of intensity-modulated radiotherapy (IMRT) 
is associated with lower renal and bowel doses compared to 
conventional planning [2, 4, 23, 24, 31, 34, 37].
RapidArc™ (RA; Varian Medical Systems, Palo Alto, 
CA, USA) is a volumetric modulated arc technique which 
allows for rapid planning and delivery of highly conformal 
intensity-modulated dose distributions using one or two 358° 
rotations of the gantry of the linear accelerator. The planning 
algorithm uses progressive sampling optimization by simulta-
neously changing the shape of the treatment aperture, dose 
rate, and rotation speed of the gantry [28]. The use of RA has 
been previously reported for patients with tumors of the head 
and neck [35], multiple brain metastases [22], lung cancer [36], 
benign intracranial tumors [21], and prostate cancer [19, 29].
In this study, we compared RA planning with conven-
tional five-field IMRT (5f-IMRT) in ten patients who had un-
dergone chemoradiotherapy for tumors of the pancreas. The 
ability of RA and conventional IMRT to reduce doses to the 
kidneys, the liver, and the small bowel was evaluated.
Patients and Methods
A retrospective planning study was performed in ten con-
secutive patients who had undergone concurrent gemcitabi-
ne-based chemoradiotherapy for locally advanced pancreatic 
carcinoma at our center. The same patients were the subject 
of an earlier comparison between three-dimensional confor-
mal radiotherapy and IMRT [34]. Details on target definition 
and radiotherapy planning scans have been described previ-
ously [34]. Briefly, clinical target volumes (CTV), consisting 
of the pancreatic tumor and enlarged regional lymph nodes, 
were contoured on all phases of a planning four-dimensional 
computed tomography (4DCT) scan that was generated dur-
ing quiet respiration. The interval between the CT phase bins 
was 1/10 of the average breathing cycle time, and the axial slice 
thickness and reconstruction index was 2.5 mm. During 4DCT 
acquisition, no oral or intravenous contrast was administered, 
because a recently acquired diagnostic contrast-enhanced CT 
or magnetic resonance imaging scan was available for all pa-
tients. Nonenlarged regional lymph nodes were not included 
in the CTV as is consistent with our institutional policy for 
chemoradiotherapy of irresectable pancreatic cancer. The in-
ternal target volume (ITV) was represented by the encompass-
ing volume of all CTVs. The planning target volume (PTV) 
was derived from the addition of a margin of 1 cm to the ITV 
in order to correct for variations in respiratory-driven tumor 
motion and patient setup errors. Organs at risk (OARs) were 
contoured on all phases of the 4DCT scan, i.e., both kidneys, 
the liver, and the stomach. A “small-bowel region” was de-
fined which consisted of the abdominal content after subtract-
ing the PTV, all OARs and the vertebral bodies, with the pos-
terior border extending to the dorsum of the lumbar vertebral 
body, but excluding the retroperitoneal space [30]. Our defi-
nition of a “small-bowel region” also included the mesentery 
and intraperitoneal fat, which is in contrast with prior reports 
describing bowel dose-volume relationships using bowel loop 
contouring [23, 24].
In contrast to the four-field IMRT (4f-IMRT) technique 
described previously [34], we applied an improved five-field 
sliding-window IMRT plan (5f-IMRT) for the ten patients, 
and compared this with RA plans for a total dose of 50.4 Gy in 
1.8-Gy fractions, in accordance with the recommendations of 
the International Commission on Radiation Units and Mea-
surements report 50. An earlier planning study had revealed 
that, for a number of these patients, the present 5f-IMRT 
plans allowed for reduced doses to OARs in comparison to 
the 4f-IMRT described previously [34] (data not shown).
Planning was primarily optimized for PTV coverage 
and for limiting each kidney volume receiving ≥ 15 Gy (V15). 
IMRT planning was performed using the Eclipse planning 
system (Varian Medical Systems). Coplanar, five-field beam 
configurations with fixed gantry positions at 30°, 100°, 180°, 
260°, and 330° were used with 6-MV photons. A renal toler-
ance dose of 15 Gy (5% risk at 5 years) and 20 Gy (50% risk at 
5 years) was assumed [7]. The hepatic tolerance dose (5% risk 
at 5 years) was set at 30 Gy for the whole organ [11]. For the 
spinal cord, a maximal dose objective of 45 Gy was accepted. 
The maximal dose objective for the stomach was 45 Gy for the 
entire organ. Doses to the small bowel were not considered in 
the optimization.
RA planning was performed using two simultaneously 
optimized volumetric arcs (RapidArc version 8.6.3, Varian 
Medical Systems) as described previously [35]. The first coun-
terclockwise arc used a 45° collimator rotation, and a second 
arc rotated clockwise with a 40° collimator rotation. No couch 
rotations or avoidance sectors were used. Similar constraint 
sets were used for both RA and 5f-IMRT plans.
Dose-volume histograms were analyzed with respect to 
PTV coverage, conformity indices (CI; the ratio between the 
volume covered by 95% of prescription dose and the PTV), 
and number of monitor units (MU) needed to deliver the dose. 
The V15, V20, and mean dose of both kidneys were computed 
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and compared. Both the mean dose and V30 were computed 
for the other OARs. Comparisons were performed using 
paired t-tests in SPSS v.15.0, and significance was assumed 
when p < 0.05.
After completion of this planning study, a patient with 
pancreatic cancer who underwent chemoradiotherapy was 
treated using RA. As is routine for all clinical RA treatments 
at our center, dosimetric verification of the plan was performed 
in a solid-water phantom on a Trilogy linear accelerator (Var-
ian Medical Systems) prior to the start of treatment. The RA 
plan was measured in two coronal planes using GafChromic 
EBT films and compared with calculated dose distributions. 
Film was used as an absolute dosimeter.
Results
RA treatment plans were consistently generated within 1 h 
planning time, which consisted largely of time for calculation. 
5f-IMRT plans generally took 1.5–2 h to complete. Tumor 
characteristics are listed in Table 1. The mean volumes of the 
CTV and PTV were 138 ± 67 cm3 (± 1 SD [standard deviation]) 
and 492 ± 189 cm3, respectively. Both IMRT and RA plans 
had excellent coverage of the PTV with ≥ 99% of the PTV 
receiving ≥ 95% of the prescribed dose. The CI obtained with 
RA was 1.09 ± 0.02, which was significantly better than that 
for 5f-IMRT plans (1.20 ± 0.10; p = 0.003). The mean number 
of MU needed to deliver the dose was significantly lower for 
RA (561 ± 95 MU for RA vs. 800 ± 209 MU for 5f-IMRT; p = 
0.009).
RA permitted significant reductions in renal V20 (Figure 1, 
Table 2). Although mean doses to both kidneys were not sig-
nificantly different, RA plans showed a significantly lower V15 
(15.9% vs. 7.2%) and V20 (6.6% vs. 2.4%) for the left kidney, 
and a lower V20 (16.8% vs. 9.9%) for the right kidney when 
compared to 5f-IMRT. Both mean doses and V30 for all other 
studied OARs, including the liver, stomach, small bowel and 
duodenum, were significantly lower with RA planning than 
with 5f-IMRT (Table 3, Figure 2). Although in three of our 
patients a similar CI was found for both RA and 5f-IMRT, not 
a single patient would have benefitted from IMRT treatment 
based on dose-volume histogram comparison of all OARs.
Table 1. Tumor characteristics. CTV: clinical target volume; PTV: plan-
ning target volume.
Tabelle 1. Tumoreigenschaften. CTV: klinisches Zielvolumen; PTV: Pla-
nungszielvolumen.
Patient # TNM Tumor subsite CTV (cm3) PTV (cm3)
  1 T4 N0 M0 Head 110 448
  2 T4 N1 M1 Body 271 862
  3 T4 N0 M0 Head   71 339
  4 T4 N1 M0 Head 132 517
  5 T4 N0 M0 Head 135 365
  6 T4 N0 M1 Head 107 432
  7 T4 N0 M0 Head 143 530
  8 T4 N0 M0 Tail   52 280
  9 T4 N0 M1 Head 207 702
10 T4 N0 M0 Head 208 674
11 T4 N0 M1 Head   78 264
Mean 138 492
Figure 1. Average dose-volume histograms (DVH) for the right and left kidney of ten patients, achieved with RA (solid line) and 5f-IMRT (dashed 
line). 
Abbildung 1. Dosis-Volumen-Histogramme (DVH; kumulierter Durchschnitt) der rechten und linken Niere von zehn Patienten für RA (durchgezo-
gene Linie) und 5f-IMRT (gestrichelte  Linie). 
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Film measurements showed that only 0.6% of the film 
surface receiving > 0.3 Gy exceeded a combination of dose dif-
ferences ≥ 3% and distance to agreement ≥ 2 mm. The patient 
was treated using daily kilovoltage images for patient setup 
correction. The “beam-on” time (after the completion of pa-
tient setup) for each fraction was < 3 min for RA, compared to 
8 min for 5f-IMRT.
Discussion
Several publications on pancreatic cancer have demonstrated 
the superiority of IMRT in reducing radiation doses to sur-
rounding normal organs in comparison to three-dimensional 
conformal radiotherapy [2, 4, 23, 24, 34]. Our analysis in ten 
patients revealed that RA allowed for an improved CI relative 
Figure 2. Average dose-volume histograms (DVH) for the bowel, 
liver, and stomach, achieved with RA (solid line) and 5f-IMRT (dashed 
line). 
Abbildung 2. Dosis-Volumen-Histogramme (DVH; kumulierter Durch-
schnitt) des Darms, der Leber und des Magens von zehn Patienten für 
RA (durchgezogene Linie) und 5f-IMRT (gestrichelte Linie). 
Table 2. Comparison of renal doses, averaged over ten patients, achie-
ved with RapidArc™ (RA) and five-field intensity-modulated radio-
therapy (5f-IMRT).
Tabelle 2. Vergleich der durchschnittlichen Nierendosis bei zehn Pati-
enten für RapidArc™ (RA) und intensitätsmodulierte Radiotherapie in 
Fünf-Felder-Technik (5f-IMRT).
5f-IMRT
Mean Range
RA
Mean Range
t-test
(RA vs. 
5f-IMRT)
Left kidney
Mean dose (Gy)
V15 (%)
V20 (%)
 8.2
15.9
 6.6
5.1–12.4
4.8–38.7
1.4–12.7
 8.8
 7.2
 2.4
6.6–10.7
0.7–16.9
0.0–10.3
0.369
0.016
0.004
Right kidney
Mean dose (Gy)
V15 (%)
V20 (%)
11.6
26.5
16.8
5.7–25.9
7.5–73.6
3.4–54.6
10.9
20.4
  9.9
4.7–25.0
1.1–72.7
0.0–49.2
0.402
0.132
0.050
Table 3. Comparison of doses to organs at risk, averaged over ten pati-
ents, achieved with RapidArc™ (RA) and five-field intensity-modulated 
radiotherapy (5f-IMRT).
Tabelle 3. Vergleich der durchschnittlichen Risikoorgandosen von zehn 
Patienten für RapidArc™ (RA) und intensitätsmodulierte Radiothera-
pie in Fünf-Felder-Technik (5f-IMRT).
5f-IMRT
Mean Range
RA
Mean Range
t-test
(RA vs. 
5f-IMRT)
Liver
Mean dose (Gy)
V30 (%)
15.1
20.9
12.0–25.2
15.4–45.3
13.8
13.8
9.5–22.4
1.6–28.2
  0.003
  0.003
Stomach
Mean dose (Gy)
V30 (%)
17.9
22.8
 5.8–24.6
 0.7–38.7
16.7
18.4
7.2–24.6
0.9–33.2
  0.017
  0.010
Small bowel
Mean dose (Gy)
V30 (%)
22.1
29.3
18.9–26.8
17.8–46.1
19.8
21.0
16.6–22.8
12.1–27.6
< 0.001
< 0.001
Duodenum
Mean dose (Gy)
V35 (%)
41.9
75.1
27.8–49.3
35.2–95.6
38.8
62.4
24.7–46.8
24.3–87.3
  0.004
  0.004
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to a 5f-IMRT plan, and that OAR doses were also significantly 
reduced. RA has now been clinically implemented, with the 
delivery of each fraction requiring < 3 min.
The main goal of our study was to investigate whether the 
increased speed in treatment planning and delivery obtained 
with RA would compromise the conformity and normal-or-
gan sparing compared to conventional IMRT. A recent paper 
questioned the ability to generate highly modulated treat-
ment plans using volumetric arc therapy [3]. Our study as well 
as recent publications in a range of tumor sites [9, 19, 21, 22, 
29, 35, 36] have clearly shown data to the contrary. We real-
ize that it may be difficult to draw firm conclusions on the 
comparison between RA and IMRT because of differences in 
optimization methods, and the use of more than five IMRT 
fields may change the comparison.
When considering dosimetric differences between RA and 
IMRT, it is also important to address motion management for 
abdominal tumors, as craniocaudal pancreatic motion of up to 
25 mm has been reported [6, 12]. Mean pancreatic motion on 
4DCT of our patients was only 9 mm, however, with extremes 
of up to 15 mm. Inadequate margins for motion may lead to 
significant underdosing, in particular when highly conformal 
treatment techniques are used. The use of respiratory gating, 
breath-hold techniques or abdominal compression can lead to 
smaller margins and thereby smaller treatment volumes. The 
former approaches can substantially prolong delivery times, 
which can increase the risk of tumor displacement during 
treatment delivery, particularly as surrogate markers such as 
abdominal wall and diaphragm poorly correlate with tumor 
mobility [12]. Earlier reports suggest that respiration-gated 
IMRT (or carbon ion therapy) leads to only very limited dosi-
metric benefits for upper abdominal tumor sites [25, 33, 34]. In 
addition, a combination of respiratory gating with arc therapy 
is technically not possible in the current version of RA.
The observed dosimetric benefit of RA over 5f-IMRT was 
reflected in a lower CI of RA plans and significant reduction 
in the V20 of the right kidney. RA plans resulted in a modest, 
but statistically significant decrease in small-bowel and spe-
cifically duodenal doses compared to 5f-IMRT. The latter are 
important, as gastrointestinal complaints are the commonest 
acute side effects of chemoradiotherapy for pancreatic can-
cer [24]. The incidence of gastrointestinal toxicity correlated 
best with the volume of small bowel receiving doses as low as 
15 Gy [1]. Our data show a superiority of RA for all doses 
> 15 Gy (Figure 2).
Our protocol calls for omission of prophylactic regional 
node irradiation, and only enlarged nodes were encompassed 
in the CTV. This limitation should be kept in mind, as the 
sensitivity of currently available imaging methods to predict 
nodal involvement is poor [17, 26]. Other groups have con-
sidered elective nodal irradiation to be appropriate due to a 
high likelihood of lymph node involvement in approximately 
75–80% of patients who underwent surgical resection for pan-
creatic tumors [5, 18]. Nevertheless, our approach results in 
the PTV encompassing the most common locations for nodal 
metastases, which are the peripancreatic and pancreaticoduo-
denal areas.
RA treatment delivery time was < 3 min in our patient, 
and this compares favorably with 5f-IMRT delivery which 
takes approximately 10 min on a Varian linear accelerator. 
Besides improving patient comfort and departmental efficien-
cy, the reduced treatment delivery will also decrease the likeli-
hood of intrafractional changes in patient position [13].
Conclusion
RA planning for advanced pancreatic cancer results in sig-
nificantly higher conformity plans than can be achieved us-
ing 5f-IMRT, which allows for increased sparing of most sur-
rounding OARs. Based on these results and the increased 
speed of planning and treatment delivery, we have adopted 
RA as our standard treatment modality for patients with ad-
vanced pancreatic cancer.
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